Cerebrospinal fluid neuroplasticity-associated protein levels in patients with psychiatric disorders: a multiplex immunoassay study

Abstract

To examine the role of neuroplasticity in the pathology of psychiatric disorders, we measured cerebrospinal fluid (CSF) neuroplasticity-associated protein levels. Participants were 94 patients with schizophrenia, 68 with bipolar disorder (BD), 104 with major depressive disorder (MDD), and 118 healthy controls, matched for age, sex, and ethnicity (Japanese). A multiplex immunoassay (22-plex assay) was performed to measure CSF neuroplasticity-associated protein levels. Among 22 proteins, 11 were successfully measured in the assay. CSF amyloid precursor protein (APP) and glial cell-derived neurotrophic factor (GDNF) levels were significantly lower in patients with schizophrenia, and CSF APP and neural cell adhesion molecule (NCAM)-1 levels were significantly lower in patients with BD, than in healthy controls (all p < 0.05). Positive and Negative Syndrome Scale total, positive, and general scores were significantly and positively correlated with CSF hepatocyte growth factor (HGF) (p < 0.01) and S100 calcium-binding protein B (S100B) (p < 0.05) levels in patients with schizophrenia. Young mania-rating scale score was significantly and positively correlated with CSF S100B level in patients with BD (p < 0.05). Hamilton Depression Rating Scale, core, sleep, activity, somatic anxiety, and delusion subscale scores were significantly and positively correlated with CSF HGF level, while sleep subscale score was positively correlated with CSF S100B and VEGF receptor 2 levels in patients with MDD (p < 0.05). Our results suggest that CSF APP, GDNF, and NCAM-1 levels are associated with psychiatric disorders, and that CSF HGF, S100B, and VEGF receptor 2 levels are related to psychiatric symptoms.

IL-33 in Mental Disorders

“…Emerging evidence highlights the role of immune response as a key factor in MDs. Immunological biomarkers seem to be related to illness progression and to treatment effectiveness; several studies suggest strong associations among IL-6, TNFa, S100b, IL 1b, and PCR with affective or schizophrenic disorders [ 6 , 7 , 8 , 9 , 10 , 11 ]. Yuan et al (2019) evaluated the meta-analysis considering inflammatory markers in mental disorders.…”

A Preliminary Investigation on Plasma Cell Adhesion Molecules Levels by Protein Microarray Technology in Major Depressive Disorder

“…At present, there are few studies on the relationship between plasma NrCAM and MDD, mainly focusing on CSF. The reason is that CSF is the optimal biological material for examination of molecular status, and has been reported to well reflect the state of the central nervous system (31)(32)(33). Many active substances, such as vascular endothelial growth factor (VEGF), Interleukin (IL)-1, IL-6, and reactive oxygen species (ROS), are closely related to the destruction of the integrity of the bloodbrain barrier (BBB), and these substances are also important members of the pathogenesis of MDD (34).…”

Multipronged Attack of Stem Cell Therapy in Treating the Neurological and Neuropsychiatric Symptoms of Epilepsy

“…Of note, GDNF may also play a role in epilepsy-induced neuropsychiatric compilations. The cerebrospinal fluid (CSF) of patients with schizophrenia, bipolar disorder, and major depressive disorder was examined ( Hidese et al, 2020 ). Concentrations of GDNF and CSF amyloid precursor protein (APP) were substantially reduced in schizophrenic patients ( Hidese et al, 2020 ).…”

“…The cerebrospinal fluid (CSF) of patients with schizophrenia, bipolar disorder, and major depressive disorder was examined ( Hidese et al, 2020 ). Concentrations of GDNF and CSF amyloid precursor protein (APP) were substantially reduced in schizophrenic patients ( Hidese et al, 2020 ). APP and neural adhesion molecule 1 (NACAM-1) was significantly downregulated in BD patients ( Hidese et al, 2020 ).…”

“…Concentrations of GDNF and CSF amyloid precursor protein (APP) were substantially reduced in schizophrenic patients ( Hidese et al, 2020 ). APP and neural adhesion molecule 1 (NACAM-1) was significantly downregulated in BD patients ( Hidese et al, 2020 ). Furthermore, utilizing stem cells to deliver these neurotrophic factors may be therapeutically potent in epilepsy.…”